Literature DB >> 22102699

Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses.

Yugo Kishida1, Atsushi Natsume, Yutaka Kondo, Ichiro Takeuchi, Byonggu An, Yasuyuki Okamoto, Keiko Shinjo, Kiyoshi Saito, Hitoshi Ando, Fumiharu Ohka, Yoshitaka Sekido, Toshihiko Wakabayashi.   

Abstract

Meningiomas are among the most common intracranial tumors and are mostly curable by surgical resection. However, some populations of meningiomas with benign histological profiles show malignant behavior. The reasons for this inconsistency are yet to be ascertained, and novel diagnostic criteria other than the histological one are urgently needed. The aim of the present study is to subclassify meningiomas from the viewpoint of gene methylation and to determine the subgroup with malignant characteristics. Thirty meningiomas were analyzed using microarrays for 6157 genes and were classified into three clusters on the basis of their methylation status; these were found to be independent of the histological grading. One of the clusters showed a high frequency of recurrence, with a marked accumulation of methylation in a subset of genes. We hypothesized that the aggressive meningiomas universally share characteristic methylation in certain genes; therefore, we chose the genes that strongly contributed to cluster formation. The quantified methylation values of five chosen genes (HOXA6, HOXA9, PENK, UPK3A and IGF2BP1) agreed well with microarray findings, and a scoring system consisting of the five genes significantly correlated with a high frequency of recurrence in an additional validation set of 32 patients. Of particular note is that three cases with malignant transformation already showed hypermethylation at histologically benign stage. In conclusion, a subgroup of meningiomas is characterized by aberrant hypermethylation of the subset of genes in the early stage of tumorigenesis, and our findings highlight the possibility of speculating potential malignancy of meningiomas by assessing methylation status.

Entities:  

Mesh:

Year:  2011        PMID: 22102699     DOI: 10.1093/carcin/bgr260

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  22 in total

1.  IMP1 3' UTR shortening enhances metastatic burden in colorectal cancer.

Authors:  Sarah F Andres; Kathy N Williams; Jacqueline B Plesset; Jeffrey J Headd; Rei Mizuno; Priya Chatterji; Ashley A Lento; Andres J Klein-Szanto; Rosemarie Mick; Kathryn E Hamilton; Anil K Rustgi
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

2.  High Level of Fasting Plasma Proenkephalin-A Predicts Deterioration of Kidney Function and Incidence of CKD.

Authors:  Christina-Alexandra Schulz; Anders Christensson; Ulrika Ericson; Peter Almgren; George Hindy; Peter M Nilsson; Joachim Struck; Andreas Bergmann; Olle Melander; Marju Orho-Melander
Journal:  J Am Soc Nephrol       Date:  2016-07-08       Impact factor: 10.121

3.  Associations of meningioma molecular subgroup and tumor recurrence.

Authors:  Mark W Youngblood; Danielle F Miyagishima; Lan Jin; Trisha Gupte; Chang Li; Daniel Duran; Julio D Montejo; Amy Zhao; Amar Sheth; Evgeniya Tyrtova; Koray Özduman; Francesco Iacoangeli; Matthieu Peyre; Julien Boetto; Matthew Pease; Timuçin Avşar; Anita Huttner; Kaya Bilguvar; Türker Kilic; M Necmettin Pamir; Nduka Amankulor; Michel Kalamarides; E Zeynep Erson-Omay; Murat Günel; Jennifer Moliterno
Journal:  Neuro Oncol       Date:  2021-05-05       Impact factor: 12.300

4.  Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis.

Authors:  Thomas Fleischer; Arnoldo Frigessi; Kevin C Johnson; Hege Edvardsen; Nizar Touleimat; Jovana Klajic; Margit Lh Riis; Vilde D Haakensen; Fredrik Wärnberg; Bjørn Naume; Aslaug Helland; Anne-Lise Børresen-Dale; Jörg Tost; Brock C Christensen; Vessela N Kristensen
Journal:  Genome Biol       Date:  2014-08-22       Impact factor: 13.583

5.  Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma.

Authors:  Adriana Olar; Khalida M Wani; Charmaine D Wilson; Gelareh Zadeh; Franco DeMonte; David T W Jones; Stefan M Pfister; Erik P Sulman; Kenneth D Aldape
Journal:  Acta Neuropathol       Date:  2017-01-27       Impact factor: 17.088

6.  Genome-wide analysis of DNA methylation identifies novel cancer-related genes in hepatocellular carcinoma.

Authors:  Masahiro Shitani; Shigeru Sasaki; Noriyuki Akutsu; Hideyasu Takagi; Hiromu Suzuki; Masanori Nojima; Hiroyuki Yamamoto; Takashi Tokino; Koichi Hirata; Kohzoh Imai; Minoru Toyota; Yasuhisa Shinomura
Journal:  Tumour Biol       Date:  2012-03-29

7.  Epigenetic evidence for distinct contributions of resident and acquired myonuclei during long-term exercise adaptation using timed in vivo myonuclear labeling.

Authors:  Kevin A Murach; Cory M Dungan; Ferdinand von Walden; Yuan Wen
Journal:  Am J Physiol Cell Physiol       Date:  2021-11-24       Impact factor: 4.249

8.  Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells.

Authors:  Kiran Kumar Velpula; Venkateswara Rao Gogineni; Arun Kumar Nalla; Dzung H Dinh; Jasti S Rao
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

9.  Loss of H3K27me3 in meningiomas.

Authors:  Farshad Nassiri; Justin Z Wang; Olivia Singh; Shirin Karimi; Tatyana Dalcourt; Nazanin Ijad; Neda Pirouzmand; Ho-Keung Ng; Andrea Saladino; Bianca Pollo; Francesco Dimeco; Stephen Yip; Andrew Gao; Kenneth D Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

10.  DNA methylation in the malignant transformation of meningiomas.

Authors:  Fan Gao; Lingling Shi; Jonathan Russin; Liyun Zeng; Xiao Chang; Shuhan He; Thomas C Chen; Steven L Giannotta; Daniel J Weisenberger; Gabriel Zada; William J Mack; Kai Wang
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.